PMID- 33496072
OWN - NLM
STAT- MEDLINE
DCOM- 20211119
LR  - 20211119
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 12
IP  - 6
DP  - 2021 Mar
TI  - Symptom trajectories during chemotherapy in patients with non-small cell lung 
      cancer (NSCLC) and the function of prolonging low dose dexamethasone in promoting 
      enhanced recovery after chemotherapy.
PG  - 783-795
LID - 10.1111/1759-7714.13830 [doi]
AB  - BACKGROUND: Lung cancer, mainly non-small cell lung cancer (NSCLC), is one of the 
      leading causes of death worldwide. Currently, chemotherapy is still the most 
      significant treatment strategy for NSCLC. However, scant attention has been paid 
      in previous studies to those patients who often experience various symptoms and 
      discomfort during chemotherapy treatment cycles. METHODS: This study included 127 
      NSCLC patients who completed an EORTC QLQ-C30 questionnaire and specifically 
      designed symptom diary. Chi-square test, factor analysis, Pearson correlation 
      coefficient and hierarchical cluster analysis were used to perform multivariate 
      analysis. RESULTS: We identified the top five most-frequent symptoms within the 
      chemotherapy cycle which included fatigue, insomnia, cough and sputum, appetite 
      loss and hypodipsia. These symptoms were at a moderate level on chemotherapy 
      treatment days 3-7, and were then reduced to a stable and lower level in the 
      following two weeks. A statistically significant difference in adverse events 
      (AEs) was found between 54 patients who received dexamethasone (treatment group) 
      and the control group: fatigue (risk ratio [RR]: 1.48; 95% confidence interval 
      [CI]: 1.120-1.961; p = 0.006), insomnia (RR: 1.34; 95% CI: 1.016-1.778; p = 
      0.038), cough and sputum (RR: 2.00; 95% CI: 1.484-2.695; p < 0.001), appetite 
      loss (RR: 1.28; 95% CI: 0.959-1.696; p = 0.095). In total, 62 patients completed 
      the EORTC QLQ-C30 scale. The functioning scales of the treatment group were 
      higher than the control population within positive effect sizes (ES: 0.1-0.8). 
      Apart from diarrhea scales, most symptom scales were lower than the control group 
      within negative effect sizes (ES: 0.1-0.9). CONCLUSIONS: In this study we 
      identified the top five most frequent post-chemotherapy AEs in a chemotherapy 
      treatment cycle and found that dexamethasone was well tolerated by NSCLC patients 
      who received platinum-based chemotherapy and substantially alleviated the symptom 
      burden and improved the health-related quality of life (HRQOL) of patients.
CI  - (c) 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Liu, Jinghao
AU  - Liu J
AD  - Department of Lung Cancer Surgery, Tianjin key laboratory of lung cancer 
      metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin 
      Medical University General Hospital, Tianjin, China.
FAU - Liu, Xingyu
AU  - Liu X
AUID- ORCID: 0000-0003-3330-4740
AD  - Department of Lung Cancer Surgery, Tianjin key laboratory of lung cancer 
      metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin 
      Medical University General Hospital, Tianjin, China.
FAU - Dong, Ming
AU  - Dong M
AD  - Department of Lung Cancer Surgery, Tianjin key laboratory of lung cancer 
      metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin 
      Medical University General Hospital, Tianjin, China.
FAU - Zhao, Honglin
AU  - Zhao H
AD  - Department of Lung Cancer Surgery, Tianjin key laboratory of lung cancer 
      metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin 
      Medical University General Hospital, Tianjin, China.
FAU - Li, Mei
AU  - Li M
AD  - Department of Lung Cancer Surgery, Tianjin key laboratory of lung cancer 
      metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin 
      Medical University General Hospital, Tianjin, China.
FAU - Zhang, Hongbing
AU  - Zhang H
AD  - Department of Lung Cancer Surgery, Tianjin key laboratory of lung cancer 
      metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin 
      Medical University General Hospital, Tianjin, China.
FAU - Ji, Huihui
AU  - Ji H
AD  - Department of Lung Cancer Surgery, Tianjin key laboratory of lung cancer 
      metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin 
      Medical University General Hospital, Tianjin, China.
FAU - Shi, Yi
AU  - Shi Y
AD  - Department of Lung Cancer Surgery, Tianjin key laboratory of lung cancer 
      metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin 
      Medical University General Hospital, Tianjin, China.
FAU - Cui, Yajie
AU  - Cui Y
AD  - Department of Lung Cancer Surgery, Tianjin key laboratory of lung cancer 
      metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin 
      Medical University General Hospital, Tianjin, China.
FAU - Wu, Di
AU  - Wu D
AD  - Department of Lung Cancer Surgery, Tianjin key laboratory of lung cancer 
      metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin 
      Medical University General Hospital, Tianjin, China.
FAU - Chen, Gang
AU  - Chen G
AD  - Department of Lung Cancer Surgery, Tianjin key laboratory of lung cancer 
      metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin 
      Medical University General Hospital, Tianjin, China.
FAU - Chen, Jun
AU  - Chen J
AD  - Department of Lung Cancer Surgery, Tianjin key laboratory of lung cancer 
      metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin 
      Medical University General Hospital, Tianjin, China.
AD  - Department of Thoracic Surgery, First Affiliated Hospital, School of Medicine, 
      Shihezi University, Shihezi, China.
LA  - eng
GR  - S2020AB1779/Key Project of Xinjiang Corps Science and Technology Research Plan/
GR  - 82072595/National Natural Science Foundation of China/
GR  - 81773207/National Natural Science Foundation of China/
GR  - 61973232/National Natural Science Foundation of China/
GR  - 17YFZCSY00840/Natural Science Foundation of Tianjin City/
GR  - 18PTZWHZ00240/Natural Science Foundation of Tianjin City/
GR  - 19YFZCSY00040/Natural Science Foundation of Tianjin City/
GR  - LX202002/Shihezi University Oasis Scholars Research Startup Project/
GR  - TJTZJH-GCCCXCYTD-2-6/Special Support Program for the High Tech Leader and Team of 
      Tianjin/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210125
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Cross-Sectional Studies
MH  - Dexamethasone/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Quality of Life
PMC - PMC7952786
OTO - NOTNLM
OT  - Chemotherapy
OT  - low dose dexamethasone
OT  - non-small cell lung cancer (NSCLC)
OT  - symptom clusters
COIS- The authors declare that they have no competing interests.
EDAT- 2021/01/27 06:00
MHDA- 2021/11/20 06:00
PMCR- 2021/03/01
CRDT- 2021/01/26 05:54
PHST- 2020/11/29 00:00 [received]
PHST- 2020/12/23 00:00 [revised]
PHST- 2020/12/23 00:00 [accepted]
PHST- 2021/01/27 06:00 [pubmed]
PHST- 2021/11/20 06:00 [medline]
PHST- 2021/01/26 05:54 [entrez]
PHST- 2021/03/01 00:00 [pmc-release]
AID - TCA13830 [pii]
AID - 10.1111/1759-7714.13830 [doi]
PST - ppublish
SO  - Thorac Cancer. 2021 Mar;12(6):783-795. doi: 10.1111/1759-7714.13830. Epub 2021 
      Jan 25.